BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC

BBOT to Participate in the Jefferies Global Healthcare Conference in London

BBOT to Participate in the Jefferies Global Healthcare Conference in London

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the Jefferies Global Healthcare Conference on Monday, November 17, at 2:30 p.m. GMT.  

A live webcast of the presentation will be accessible on the “” page of the BBOT website at . A replay of the webcast will be available for at least 90 days following the event.

About BBOT

BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit  and follow us on .

BBOT Contacts:

Investor Contact:

Heather Armstrong, Head of Investor Relations

BBOT



Media Contact:

Jake Robison

Inizio Evoke Comms



EN
03/11/2025

Underlying

BBOTBRIDGEBIO ONCOLOGY THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BRIDGEBIO ONCOLOGY THERAPEUTICS INC

 PRESS RELEASE
Free
BBOT BRIDGEBIO ONCOL...

BBOT Announces Publication in Cancer Discovery Highlighting Preclinica...

BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO...

March 6, 2026 1 EN
Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
SHOP SHOPIFY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
ETSY ETSY INC.
EBAY EBAY INC.
NFLX NETFLIX INC.
CCRN CROSS COUNTRY HEALTHCARE INC.
WVE WAVE LIFE SCIENCES
CVNA CARVANA CO. CLASS A
AMZN AMAZON.COM INC.
BKNG BOOKING HOLDINGS INC.
CHWY CHEWY INC. CLASS A
STTK SHATTUCK LABS
KROS KEROS THERAPEUTICS
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
DAWN DAY ONE BIOPHARMACEUTICALS INC
XMTR XOMETRY
TNGX INC.
ELYM TANGO THERAPEUTICS
APP INC
TTD ELIEM THERAPEUTICS INC
CMPX APPLOVIN CORP
RGTI THE TRADE DESK
EWTX INC.
CART COMPASS THERAPEUTICS
TLX RIGETTI COMPUTING INC
BBOT EDGEWISE THERAPEUTICS INC
MAPLEBEAR INC.
TELIX PHARMACEUTICALS LIMITED
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
03/06/26 March 6, 2026 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
03/06/26 March 6, 2026 1 EN
 PRESS RELEASE
Free
BBOT BRIDGEBIO ONCOL...

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and U...

BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520’s differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response i...

March 5, 2026 1 EN
 PRESS RELEASE
Free
BBOT BRIDGEBIO ONCOL...

BBOT to Participate in Upcoming Investor Healthcare Conferences

BBOT to Participate in Upcoming Investor Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company’s participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. ET. Leerink Global Healthcare...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch